Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects.
Recent evidence shows tetracyclines have anticollagenolytic activity that may be clinically effective in disease treatment. This led us to use systemic tetracycline (oral tetracycline hydrochloride 1 g daily divided into 4 doses) as adjunctive therapy in treating 18 patients with persistent corneal epithelial defects. Fourteen of 18 patients healed their defects; within 48 hours (9 patients) and within two weeks (the other 5 responding patients). Two patients showed no effect and two showed disease progression.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D004848:Epithelium / Q000473:pathology; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013752:Tetracycline / Q000009:adverse effects / Q000627:therapeutic use*
D013752:Tetracycline